Emadine Euroopan unioni - suomi - EMA (European Medicines Agency)

emadine

immedica pharma ab - emedastine difumarate - konjunktiviitti, allerginen - silmätautien - kausiluonteisen allergisen sidekalvotulehduksen oireellinen hoito.

Betoptic S 2.5 mg/ml silmätipat, suspensio Suomi - suomi - Fimea (Suomen lääkevirasto)

betoptic s 2.5 mg/ml silmätipat, suspensio

immedica pharma ab - betaxolol hydrochloride - silmätipat, suspensio - 2.5 mg/ml - betaksololi

Betoptic S 2.5 mg/ml silmätipat, suspensio, kerta-annospakkaus Suomi - suomi - Fimea (Suomen lääkevirasto)

betoptic s 2.5 mg/ml silmätipat, suspensio, kerta-annospakkaus

immedica pharma ab - betaxolol hydrochloride - silmätipat, suspensio, kerta-annospakkaus - 2.5 mg/ml - betaksololi

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Euroopan unioni - suomi - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - klopidogreelin hydrokloridi - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitromboottiset aineet - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Darunavir Medical Valley 800 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

darunavir medical valley 800 mg tabletti, kalvopäällysteinen

medical valley invest ab - darunavir propylene glycolate - tabletti, kalvopäällysteinen - 800 mg - darunaviiri

Quetiapin Medical Valley 50 mg depottabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

quetiapin medical valley 50 mg depottabletti

medical valley invest ab - quetiapine fumarate - depottabletti - 50 mg - ketiapiini

Quetiapin Medical Valley 150 mg depottabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

quetiapin medical valley 150 mg depottabletti

medical valley invest ab - quetiapine fumarate - depottabletti - 150 mg - ketiapiini

Quetiapin Medical Valley 200 mg depottabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

quetiapin medical valley 200 mg depottabletti

medical valley invest ab - quetiapine fumarate - depottabletti - 200 mg - ketiapiini

Quetiapin Medical Valley 300 mg depottabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

quetiapin medical valley 300 mg depottabletti

medical valley invest ab - quetiapine fumarate - depottabletti - 300 mg - ketiapiini

Quetiapin Medical Valley 400 mg depottabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

quetiapin medical valley 400 mg depottabletti

medical valley invest ab - quetiapine fumarate - depottabletti - 400 mg - ketiapiini